Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1984 Sep;17(3):190–194. doi: 10.1007/BF00205484

Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients

Bertrum Sheid 1,✉, John Boyce 2
PMCID: PMC11039279  PMID: 6332671

Abstract

Ascitic fluid from women with advanced ovarian carcinomas was shown to contain factor(s) which inhibit(s) T lymphocyte mitogenesis. The factor(s) was (were) demonstrated to be associated with the infiltrating macrophages. The inhibition was reversible and inhibited mitogenesis at some late event in the cell cycle. The inhibitory substance(s) was (were) noncytotoxic, dialyzable, heat-stable at 70° C for 10 min (but unstable at 100° C for 15 min), and partially resistant to protease treatment (55%–70%). Further experiments demonstrated that macrophages isolated from the ascitic fluid of patients with cirrhosis of the liver also released factor(s) which inhibit(s) T lymphocyte mitogenesis. On the basis of our data and data from other investigators, we propose that in advanced human ovarian cancer of epithelial origin, macrophages which infiltrate the ascitic fluid elaborate nonspecific inhibitors of T lymphocyte blastogenesis within the proximal environment, resulting in localized immunosuppression and the subsequent enhancement of metastasis within the peritoneal cavity, the tumor cells themselves being resistant to the cytocidal action of the macrophages due to genetic selection and/or their inherent biochemical ability to circumvent normal immunosurveillance mechanisms. This may account, at least in part, for the rapid metastasis and poor prognosis of human ovarian adenocarcinomas.

Keywords: Ovarian Cancer, Ovarian Carcinoma, Ascitic Fluid, Ovarian Cancer Patient, Human Ovarian Cancer

References

  • 1.Ablin RJ. Immunobiology of the prostate. In: Tannebaum M, editor. Urologic pathology — The prostate; Vol 1. Philadelphia: Lea and Febiger; 1977. pp. 33–58. [Google Scholar]
  • 2.Badger AM, Cooperband SR, Merluzzi VJ, Glasgow AH. Immunosuppressive activity of ascitic fluid from patients with cancer metastatic to the peritoneum. Cancer Res. 1977;37:1200. [PubMed] [Google Scholar]
  • 3.Bormer OP. Purification of a cytotoxic factor from human and rat tissues. Br J Cancer. 1976;34:359. doi: 10.1038/bjc.1976.178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Boyum A. Separation of white blood cells. Nature. 1954;204:793. doi: 10.1038/204793a0. [DOI] [PubMed] [Google Scholar]
  • 5.Carr I. Macrophages in human cancer. A review. In: James K, McBride B, Stuart A, editors. The macrophage and cancer. Edinburgh: University Press; 1977. pp. 364–374. [Google Scholar]
  • 6.Eccles SA, Alexander P. Macrophage content of tumors in relation to metastatic spread and host immune reaction. Nature. 1974;250:667. doi: 10.1038/250667a0. [DOI] [PubMed] [Google Scholar]
  • 7.Eilber FR, Merton DL. Impaired immunological reactivity and recurrence following cancer surgery. Cancer. 1970;25:362. doi: 10.1002/1097-0142(197002)25:2<362::aid-cncr2820250213>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  • 8.Evans R. Tumor macrophages in host immunity to malignancies. In: Find MA, editor. The macrophage in neoplasia. New York: Academic Press; 1976. pp. 27–42. [Google Scholar]
  • 9.Friedman H, Ceglowski WS (1976) Immunologic aspects of neoplasia. In: Beers W (ed) MD Anderson Symposium. Baltimore, pp 253–291
  • 10.Gardner RJ, Preston FW. Prolonged skin homograft survival in advanced cancer and cirrhosis of the liver. Surg Gynecol Obstet. 1962;115:394. [PubMed] [Google Scholar]
  • 11.Harris J, Bagai RC. Immune deficiency states associated with malignant disease in man. Med Clin North Am. 1972;56:501. doi: 10.1016/s0025-7125(16)32410-5. [DOI] [PubMed] [Google Scholar]
  • 12.Gorelik F, Wittrout RH, Brunda MJ, Holden HT, Heberman RB. Augmentation of metastasis formation by thioglycollate-elicited macrophages. Int J Cancer. 1982;29:575. doi: 10.1002/ijc.2910290514. [DOI] [PubMed] [Google Scholar]
  • 13.Heberman RB. Immunologic approaches to the diagnosis of cancer. Cancer. 1976;37:549. doi: 10.1002/1097-0142(197601)37:1+<549::aid-cncr2820370720>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  • 14.Hersch EM, Drewinko B. Specific inhibition of lymphocyte blastogenic responses to mutagens by a factor produced by cultured human malignant lymphoma cells. Cancer Res. 1974;34:215. [PubMed] [Google Scholar]
  • 15.Hess AD, Gall SA, Dawson JR. Inhibition of in vitro lymphocyte function by cystic and ascitic fluids from ovarian cancer patients. Cancer Res. 1979;39:2381. [PubMed] [Google Scholar]
  • 16.Hess AD, Gall SA, Dawson JR. Partial purification and characterization of a lymphocyte-inhibiting factor(s) in ascitic fluids from ovarian cancer patients. Cancer Res. 1980;40:1842. [PubMed] [Google Scholar]
  • 17.Hewlit G, Opitz H, G Schlumberger HG, Lemke L. Growth regulation of a murine lymphoma line by a 2-mercaptoethanol or macrophage-activated serum factor. Eur J Immunol. 1977;7:781. doi: 10.1002/eji.1830071107. [DOI] [PubMed] [Google Scholar]
  • 18.Kamo I, Friedman H. Characterization of a dialyzable immunosuppressive fraction from mastocytoma culture supernatants. Proc Soc Exp Biol Med. 1977;156:177. doi: 10.3181/00379727-156-39901. [DOI] [PubMed] [Google Scholar]
  • 19.Kersey JH, Specter BD, Good RA. Immunodeficiency and cancer. Adv Cancer Res. 1973;18:211. doi: 10.1016/s0065-230x(08)60753-8. [DOI] [PubMed] [Google Scholar]
  • 20.Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265. [PubMed] [Google Scholar]
  • 21.Mantovani A. In vitro effects on tumor cells of macrophages isolated from early passage chemically-induced murine sarcoma and from its spontaneous metastasis. Int J Cancer. 1981;27:221. doi: 10.1002/ijc.2910270215. [DOI] [PubMed] [Google Scholar]
  • 22.Mantovani A, Polentarutti N, Peri G, Shavit ZB, Vecchi A, Bolis G, Mangioni C. Cytotoxicity on tumor cells of peripheral blood monocytes and tumor-associated macrophages in patients ovarian tumors. INCI. 1980;64:1307. doi: 10.1093/jnci/64.6.1307. [DOI] [PubMed] [Google Scholar]
  • 23.Mantovani A, Gaivazzi R, Allessandri G, Spreafico F, Garattini S. Characterization of tumor lines derived from spontaneous metastasis of a transplanted murine sarcoma. Eur J Cancer. 1981;17:71. doi: 10.1016/0014-2964(81)90213-9. [DOI] [PubMed] [Google Scholar]
  • 24.Miller DC. The immunologic capability of patients with lymphoma. Cancer Res. 1968;28:1441. [PubMed] [Google Scholar]
  • 25.Moore K, Moore M. Intra-tumor host cells of transplanted rat neoplasms of different immunogenicity. Int J Cancer. 1977;19:1803. doi: 10.1002/ijc.2910190610. [DOI] [PubMed] [Google Scholar]
  • 26.Namba Y, Hanooka M. Immunocytology of cultured IgM-forming cells of mouse. 1. Requirement of phagocytic cell factor for the growth of IgM-forming cells in tissue culture. J Immunol. 1972;109:1193. [PubMed] [Google Scholar]
  • 27.Nathan CF, Terry WD. Differential stimulation of murine lymphoma growth in vitro in normal and BCG-activated macrophages. J Exp Med. 1975;142:887. doi: 10.1084/jem.142.4.887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Peri G, Polentarutti N, Sessa C, Mangioni C, Mantovani A. Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: augmentation by interferon, lymphokines and endotoxin. Int J Cancer. 1981;28:143. doi: 10.1002/ijc.2910280206. [DOI] [PubMed] [Google Scholar]
  • 29.Prat M, Tarone G, Comoglio PM. Mouse fibroblasts transformed by Rous sarcoma virus express a virus-specific non-virion transplantation antigen. Int J Cancer. 1981;27:797. doi: 10.1002/ijc.2910270611. [DOI] [PubMed] [Google Scholar]
  • 30.Remacle-Bonnet MM, Pommier GJ, Kaplanski S, Range RJ, Depieds RC. Inhibition of normal allogenic lymphocyte mitogenesis by a soluble inhibition factor from human colonic cacinoma. J Immunol. 1976;117:1145. [PubMed] [Google Scholar]
  • 31.Renck CM, Gupta RK, Morton DL. Inhibition of normal allogenic mitogenesis by a factor released from human tumors in culture. Cancer Immunol Immunother. 1981;11:7. [Google Scholar]
  • 32.Salmon SE, Hamburger AW. Immunoproliferation and cancer; a common macrophage-derived promoter substance. Lancet. 1978;I:1289. doi: 10.1016/s0140-6736(78)91270-9. [DOI] [PubMed] [Google Scholar]
  • 33.Ting CC, Tsai SC, Rogers MJ. Host control of tumor growth. Science. 1977;197:571. doi: 10.1126/science.267328. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES